TRIFECTA-SCC
A Phase II Study of Triplet Immunotherapy For Exhausted Cell Targets in Advanced Squamous Cell Carcinoma (TRIFECTA-SCC)
Sponsor study identifier
interventional
26
1 country
1
Study Start
February 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
August 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 1, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The investigators propose a phase II signal-finding study, TRIFECTA-SCC, to determine whether four 100 mg IV every 6 week doses of vilastobart plus six every 4 week doses of Opdualag with induction radiotherapy can lead to ≥50% 6-month progression-free survival for patients with recurrent and/or metastatic squamous cell carcinoma. Patients with pathology-confirmed squamous cell carcinoma, previously untreated in the recurrent and/or metastatic setting, and adequate organ function will be included.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 1, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 20, 2026
Actual (reported)October 27, 2026
Actual (reported)February 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
August 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
February 1, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Six-month Progression-Free Survival
This measure is the number of subjects without progression at six months.
Up to six calendar months and 14 days after the first radiation fraction
Patients will receive 35 Gy in five fractions to all eligible recurrent/metastatic lesions. Post-RT immunotherapy should start within 72 hours after the final fraction.
35 Gy in five fractions to all eligible lesions.
four vilastobart 100 mg IV doses every 6 weeks at Weeks 0, 6, 12, and 18
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Treatment programme
Induction radiotherapy
The registry describes a treatment programme. Individual components, doses and actual administration are not established by this entry.
Registry study type: Interventional
View registry recordFroedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Stuart J Wong, MD
Medical College of Wisconsin
First Submitted
October 20, 2026
First Posted
October 27, 2026
Study Start
February 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
August 1, 2029
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
six Opdualag doses every 4 weeks at Weeks 0, 4, 8, 12, 16, and 20
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 1, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 27, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: